NKTR · Nektar Therapeutics
$46.99
-13.56 (-22.39%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$1.95B
Shares
34.14M
Volume · Oct 1
6.27M
Avg daily vol (3M)
998.4K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$46.99
Open$55.41
Day$46.29–56.69
52W close$35.12–100.35
Avg vol 30d1.3M
Short int5.7M · 16.8% float · 7.6d
Short vol48%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 6 wks
filed Aug 14, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+6.4%
Trailing year
Short interest
16.8%
Latest settlement · 7.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−33%
below
RSI (14)
24
oversold
MACD trend
Negative
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−35%
trailing
6-month return
−39%
trailing
YTD return
+11%
this year
Relative strength
−52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $70 › 200d $65 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +71 funds added
Insider flow
Distributing
Net -$43.5K over 90 days · 100% sells
Short interest
Falling
16.80% of float · ▼ -5.5% MoM · 7.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
243 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+86%
Y/Y
EPS growth
−12%
Y/Y
Free cash flow
$-208.7M
Balance sheet
$195.5M
net debt
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 13, 2026
year-end 2026
Cash and investments
$815M – $840M
full year 2026
R&D expense
Initiated
$210M – $230M
G&A expenses
Initiated
$60M – $65M
2026
Non-cash interest expense
$30M – $35M
Guided vs delivered
· last 2 settled
GAAP revenue
full year 2021
guided $100M
$101.91M
Beat +1.9%
Full year 2020 GAAP revenue
full year 2020
guided $140M – $145M
$152.92M
Beat +7.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
24
Neutral
MACD trend
Negative
Bearish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $70 › 200d $65 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +71 funds added
Insider flow
Distributing
Net -$43.5K over 90 days · 100% sells
Short interest
Falling
16.80% of float · ▼ -5.5% MoM · 7.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
243 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $35
Now $47 · 18%
Range high $100
vs 200-day avg -28%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NKTR
this stock
Nektar Therapeutics
|
$1.95B | +11.1% | +86.0% | — | 16.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NKTR | -20.9% | -35.4% | -39.4% | -22.4% | +11.1% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -20.5% | -35.3% | -51.8% | -22.6% | -0.9% |